Seok Hwan Chang

Ms. Seok Hwan Chang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LSLee Sun-Young
Lee Sun-Young
JKJong Chul Kim
Jong Chul Kim
MCMi Ran Choi
Mi Ran Choi
JSJiseo Song
Jiseo Song
MKMoonhang Kim
Moonhang Kim
SLSang-rae Lee
Sang-rae Lee
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-β (Aβ) pathology, synaptic degeneration, impaired neurogenesis, and chronic neuroinflammation. KBN2202, a small-molecule salicylic acid derivative [2-[(2-naphthalen-1-yloxy)ethyl]amino]-4-hydroxybenzoic acid], was investigated for its potential as a multi-target therapeutic agent in advanced-stage AD. To this end, 9-month-old 5xFAD mice with established AD-like pathology received daily oral KBN2202 (5 or 20 mg/kg) or vehicle for 12 weeks. KBN2202 demonstrated broad histopathological benefits. It preserved hippocampal CA1 cytoarchitecture and increased dendritic length in cortical neurons. Neurogenic activity was also enhanced, with elevated doublecortin (DCX) expression in the subventricular zone (SVZ). At the molecular level, KBN2202 reduced amyloid precursor protein C-terminal fragments (APP-CTFs), key intermediates in amyloidogenic processing, and histological staining confirmed a significant reduction in fibrillar and diffuse Aβ plaque burden in the cortex and hippocampus. Furthermore, KBN2202 attenuated astrocytic and microglial activation, indicating suppression of chronic neuroinflammation. In behavioral assessments, KBN2202 significantly improved recognition memory in the novel object recognition (NOR) test, while Y-maze performance remained unchanged. Overall, the compound exhibited robust neuroprotective, pro-neurogenic, anti-amyloid, and anti-inflammatory effects. These findings support the therapeutic potential of KBN2202 as a multi-functional candidate for symptomatic-stage AD.

Verified
Journal Article
Open access
PDF file
MCMi Ran Choi
Mi Ran Choi
JKJihun Kim
Jihun Kim
CPChaeeun Park
Chaeeun Park
SCSeok Hwan Chang
Seok Hwan Chang
HKHan-Na Kim
Han-Na Kim
SLSang-rae Lee
Sang-rae Lee
Cannabis vaping, particularly involving cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), rapidly delivers highly concentrated cannabinoids to the brain, potentially affecting the hippocampus. This study examined differential expression of long noncoding RNAs (lncRNAs) and mRNAs in the hippocampus after acute exposure to vaporized CBD or THC. Male ICR mice were exposed to vaporized CBD or THC (50 mg, n = 5/group), and hippocampal tissues were collected at 1, 3, and 14 days post-exposure. Total RNA sequencing was conducted on day 1 samples, and selected transcripts were validated using qRT-PCR across multiple time points. CBD led to significant up- or downregulation of L3mbtl1, Wnt7a, and Camk2b at day 1. However, Wnt7a showed gradual recovery at days 3 and 14. In the THC group, Grin2a, Gria3, and Golga2 were significantly upregulated, while Drd1, Drd2, Gnal, and Adcy5 were significantly downregulated at day 1. Time-course analysis showed that Drd2 expression returned to baseline by day 14, whereas Adcy5 remained persistently downregulated through days 3 and 14. In the CBD group, NONMMUT069014.2 was upregulated, while NONMMUT033147.2 and NONMMUT072606.2 were downregulated at day 1; notably, NONMMUT072606.2 showed a transient increase at day 3 before returning to baseline. In the THC group, NONMMUT085523.1 and NONMMUT123548.1 were upregulated, whereas NONMMUT019734.2, NONMMUT057101.2, and NONMMUT004928.2 were downregulated, with most showing gradual recovery by day 14. Correlation analysis revealed that THC-responsive lncRNAs—including NONMMUT004928.2, NONMMUT057101.2, and NONMMUT019734.2—were strongly associated with downregulated mRNAs such as Drd2 and Adcy5. These findings highlight cannabinoid-specific hippocampal transcriptomic responses and suggest potential regulatory roles for lncRNA–mRNA interactions in cannabinoid-induced neural changes.

Verified
Journal Article
Open access
PDF file
MKMoonhang Kim
Moonhang Kim
JHJeonghyeon Heo
Jeonghyeon Heo
SCSeok Hwan Chang
Seok Hwan Chang
LSLee Sun-Young
Lee Sun-Young
JKJihun Kim
Jihun Kim
SLSang-rae Lee
Sang-rae Lee
Obesity treatments increasingly target multiple pathways beyond appetite suppression. We evaluated KBN2202, a salicylate-derived small molecule, in a high-fat diet (60% kcal from fat) mouse model using female and male C57BL/6J mice treated for 8 weeks with oral KBN2202 (20 mg/kg/day) or a matched-volume vehicle (1% DMSO/PBS). Body weight was recorded weekly, and food intake was measured daily; serum hormones and cytokines, adipose tissue histology, and open-field behavior were assessed at the end of the study. Under our experimental conditions, HFD increased body weight and gonadal white adipose tissue (gWAT)/brown adipose tissue (BAT) mass in females, whereas males showed only modest HFD-associated weight gain and did not develop a clear obesity phenotype. KBN2202 significantly reduced peri-ovarian gWAT mass and adipocyte size without altering overall body weight. In females, circulating glucagon-like peptide-1 (GLP-1) increased, uncoupling protein 1 (UCP1) in gWAT showed a non-significant upward trend, and serum TNF-α was selectively decreased, while MCP-1 and IL-1β were unchanged. Locomotor activity was unaltered, and anxiety-like behavior was reduced. Male mice did not show comparable adipose effects. These findings indicate depot-specific, peripheral modulation of adipose remodeling, hormonal balance, and inflammatory tone by KBN2202, supporting its further investigation as an adipose-targeted metabolic modulator complementary to incretin-based therapies.

24 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MKMoonhang Kim
Moonhang Kim
JHJeonghyeon Heo
Jeonghyeon Heo
SCSeok Hwan Chang
Seok Hwan Chang
LSLee Sun-Young
Lee Sun-Young
JKJihun Kim
Jihun Kim
SLSang-rae Lee
Sang-rae Lee
Obesity treatments increasingly target multiple pathways beyond appetite suppression. We evaluated KBN2202, a salicylate-derived small molecule, in a high-fat diet (60% kcal) mouse model using female and male C57BL/6J mice treated for 8 weeks with oral KBN2202 (20 mg/kg/day) or matched-volume vehicle (1% DMSO/PBS). Body weight and food intake were tracked weekly; serum hormones/cytokines, adipose tissue histology, and open-field behavior were assessed at study end. KBN2202 significantly reduced peri-ovarian gonadal white adipose tissue (gWAT) mass and adipocyte size in females without altering overall body weight. Circulating glucagon-like peptide-1 (GLP-1) increased, uncoupling protein 1 (UCP1) in gWAT showed a non-significant upward trend, and serum TNF-α was selectively decreased, while MCP-1 and IL-1β were unchanged. Despite higher apparent food intake, locomotor activity was unaltered and anxiety-like behavior was reduced. Male mice did not show comparable adipose effects. These findings indicate depot-specific, peripheral modulation of adipose remodeling, hormonal balance, and inflammatory tone by KBN2202, supporting its further investigation as an adipose-targeted metabolic modulator complementary to incretin-based therapies.

Verified
Journal Article
Open access
PDF file
MKMoonhang Kim
Moonhang Kim
JHJeonghyeon Heo
Jeonghyeon Heo
SCSeok Hwan Chang
Seok Hwan Chang
LSLee Sun-Young
Lee Sun-Young
JKJihun Kim
Jihun Kim
SLSang-rae Lee
Sang-rae Lee
Obesity is characterized by pathological adipose tissue expansion and dysregulated energy homeostasis. In this study, we examined whether KBN2201 attenuates high-fat diet (HFD)-induced obesity-associated phenotypes and whether these effects are accompanied by changes in appetite-regulatory markers. C57BL/6J mice were fed a normal chow diet or HFD and orally administered vehicle or KBN2201 (20 mg/kg/day) for 12 weeks. In male mice, KBN2201 reduced HFD-induced body weight gain, adipose tissue accumulation, and adipocyte hypertrophy. KBN2201 was also associated with lower cage-level caloric intake under HFD-fed conditions. In epididymal white adipose tissue (eWAT), KBN2201 suppressed Srebf1 expression and reduced HFD-induced increases in Tnf and Tgfb1 expression. In the colon, KBN2201 further increased Pyy mRNA expression, and a positive mRNA-level association was observed between colonic Pyy and Npy2r expression in NTS-containing brainstem tissue. Behavioral analyses provided no evidence of overt locomotor suppression under the present experimental conditions. These findings suggest that KBN2201 attenuates HFD-induced obesity-associated phenotypes in male mice, accompanied by a lower cage-level food intake pattern, reduced adipose tissue expansion, and changes in the expression of colonic Pyy and NTS-containing brainstem Npy2r.